viewKromek Group PLC

Kromek Group aims to make progress across all three divisions


  • Developer and supplier of radiation detection products
  • Sells to medical, security screening and nuclear markets
  • Operates in UK and US with international distribution network

Quick facts: Kromek Group PLC

Price: 12.8 GBX

Market: AIM
Market Cap: £44.11 m


What Kromek does

Kromek Group PLC (LON:KMK) is a developer and supplier of radiation detection products for the medical, security screening and nuclear markets.

The company’s products are based on cadmium zinc telluride (CZT), an alloy used primarily for x-ray and gamma radiation detection, as well as other technologies.

The group has operations in the UK and the US and sells its products internationally through a network of distributors, original equipment manufacturers (OEMs) and direct sales.


How is it doing

In early summer, the company was awarded an extension to its contract with the Defense Advanced Research Projects Agency (DARPA) to detect and identify pathogens in an urban environment.

Under the new deal, Kromek said it will be awarded up to US$5.2mln to further work on its mobile wide-area bio-surveillance system capable of detecting airborne pathogens.

In a full-year trading update at the start of the month, the firm said it had started the second half of its current financial year with “increasing commercial momentum” and had not experienced any material impact from the coronavirus pandemic until the end of February.

As a result, the firm said it now expects to report full-year revenues of £14.5mln, similar to the prior year, while adjusted underlying earnings (EBITDA) are predicted to be breakeven.

Kromek is also helping in the effort to combat coronavirus by turning its manufacturing efforts over to producing medical ventilators, which will be made under licence machinery developed by the Japanese firm Metran.

The company said it has received “significant interest” in the ventilators and is on track to produce at least 2,000 units by autumn.


Watch the interview


What the boss says: Arnab Basu, chief executive

Speaking on the ventilator manufacturing deal, the CEO said: “By combining our existing manufacturing skills with Metran's proven technology, we expect to commence the manufacture of these robust ventilators from next week and deliver in a rapid manner,” he added.

“Any procurement of this equipment from Kromek is expected to have the additional benefit of safeguarding and creating employment in the North East as well as contributing to this region's fight against COVID-19. We look forward to the ongoing relationship with Metran."


Inflexion points

  • Additional orders in all three divisions
  • Airport safety standards tightening around the world
  • New opportunities in biological detection
  • The company has new manufacturing plants in the US and UK

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kromek Group PLC named herein, including the promotion by the Company of Kromek Group PLC in any Content on the Site, the Company receives from...


New Kromek chairman Sir Peter Williams excited by opportunity

Proactive Investors speaks to Sir Peter Williams, science and engineering veteran and newly appointed chairman of Kromek (LON:KMK). Williams, who has also been chairman and chief executive of Oxford Instruments (LON:OXIG), says he hopes to sharpen the commercial and strategic focus of the...

on 09/28/2015

2 min read